drug · small molecule

PROSTIN VR PEDIATRIC

updated 2mo ago

by $PFE PFIZER INC🔗 ChEMBL

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 12 investigational indications.

targets

Prostaglandin E2 receptor EP2 subtypeProstaglandin E2 receptor EP1 subtype

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

PROSTIN VR PEDIATRIC

trade names

Alprostadil, Caverject, Caverject impulse, Edex, Prostin vr, Prostin vr pediatric

generic

ALPROSTADIL

MOA

Prostanoid EP2 receptor agonist; Prostanoid EP1 receptor agonist

indication

INDICATIONS AND USAGE PROSTIN VR PEDIATRIC Sterile Solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. In infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment pO 2 values; that is, patients with low pO 2 values respond best, and patients with pO 2 values of 40 torr or more usually have little response. PROSTIN VR PEDIATRIC should be administered only by trained personnel in facilities that provide pediatric intensive care.

PROSTIN VR PEDIATRIC

targets

all catalysts(0)

News(0)

comments(0)

Report a data issue

🐶 often sniffed alongside

Trials studying PROSTIN VR PEDIATRIC